AYTU - Aytu BioPharma, Inc.
Chart Events
Fast Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.6700 |
| Open | 1.7219 |
| Bid | 1.6900 x 900 |
| Ask | 1.8000 x 800 |
| Day's Range | 1.6998 - 1.7000 |
| 52 Week Range | 1.4000 - 16.2000 |
| Volume | |
| Avg. Volume | 80,960 |
| Market Cap | 6.426M |
| Beta (5Y Monthly) | -0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.8100 |
| Earnings Date | May 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.00 |
Fair Value
Related Research
Insider MonkeyAytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2023 Earnings Call Transcript May 11, 2023 Aytu BioPharma, Inc. misses on earnings expectations. Reported EPS is $-1.93 EPS, expectations were $-0.63. Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q3 Results Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Please note this […]
- InvestorPlace
AYTU Stock Earnings: Aytu Misses EPS, Revenue Estimates
Aytu Biopharma (NASDAQ:AYTU) just posted results for its fiscal third quarter. Aytu reported a loss per share of $1.93. This was much worse than the analyst estimate for a loss per share of 63 cents. The company reported revenue of $22.73 million. This was also worse than the analyst estimate for revenue of $28 million. You can read the full Aytu press release here. On the date of publication, Sarah Smith did not have (either directly or indirectly) any positions in the securities mentioned in t
ACCESSWIREAytu BioPharma Reports Third Quarter of Fiscal Year 2023 Financial Results
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended March 31, 2023.
- ACCESSWIRE
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its third quarter fiscal year 2023, ended March 31, 2023, after the market close on Thursday, May 11, 2023.
- ACCESSWIRE
Aytu BioPharma Subleases a Portion of Its Manufacturing Facility
/ Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, entered into an agreement with AMT Manufacturing Solutions, LLC ("AMTMS"), a newly established, full service Contract Manufacturing Organization ("CMO"), to sublease 22,909 square feet of Aytu's Grand Prairie, TX manufacturing facility.
- ACCESSWIRE
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site Transfer
/ Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, received U.S. Food & Drug Administration ("FDA") approval of the Adzenys XR-ODT® ("Adzenys") Prior Approval Supplement ("PAS"). This approval enables the transfer of manufacturing of Adzenys to the Company's third-party manufacturer.
ZacksAytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Aytu BioPharma Inc. (AYTU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Insider MonkeyAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2023 Earnings Call Transcript February 21, 2023 Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2023 Q2 Results Conference Call. At this time, all participants are on a listen-only mode. . Please note this conference is being recorded. I’ll now turn the conference over to your host, Roger Weiss. You […]
- ACCESSWIRE
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the quarter ended December 31, 2022.
- ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
/ Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for the quarter ended December 31, 2022, after the market close today, Tuesday, February 21, 2023.
- ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, has announced the delayed filing of its Form 10-Q for its second quarter fiscal year 2023, ended December 31, 2022 to allow for additional assessment and management review time on an accounting matter.
- ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results for its second quarter fiscal year 2023, ended December 31, 2022, after the market close on Tuesday, February 14, 2023.
Simply Wall St.Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Expected To Breakeven In The Near Future
We feel now is a pretty good time to analyse Aytu BioPharma, Inc.'s ( NASDAQ:AYTU ) business as it appears the company...
- ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that it received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it has regained compliance with the Nasdaq's minimum bid price requirement.
- ACCESSWIRE
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.
- ACCESSWIRE
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Millions of ADHD patients in the United States rely on FDA approved treatments to control their ADHD symptoms and many of them are currently struggling to fill their prescription due to a prolonged supply disruption for generic Adderall XR (mixed salts of a single-entity amphetamine product) extended-release capsules, CII. Many of these patients may not be aware that there's an FDA-approved, bioequivalent treatment option which is widely available.
- ACCESSWIRE
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis.
Insider MonkeyAytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2023 Earnings Call Transcript November 14, 2022 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.18. Operator: Good afternoon, ladies and gentlemen, and welcome to the Aytu BioPharma Fiscal 2023 Q1 Results Call. At this time, all participants are placed on a listen-only mode and the […]
- ACCESSWIRE
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced the highest weekly prescription total for Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets, CII, since the inception of the Aytu RxConnect patient support program.
- ACCESSWIRE
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's
- Simply Wall St.
US$5.50: That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After Its Latest Results
Aytu BioPharma, Inc. ( NASDAQ:AYTU ) just released its quarterly report and things are looking bullish. The results...
- ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today it has ranked 94th on the Deloitte Technology Fast 500™.
- ACCESSWIRE
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
/ Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the passing of Michael Macaluso, Co-Founder and founding board member of Aytu.
- Simply Wall St.
Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations
Aytu BioPharma ( NASDAQ:AYTU ) First Quarter 2023 Results Key Financial Results Revenue: US$27.7m (up 26% from 1Q...
- ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced financial and operational results for the first quarter of fiscal year 2023 for the period ended September 30, 2022.